A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

(2017) Roy Fleischmann et al.   LANCET

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

(2017) A. J. Kivitz et al.   Arthritis & Rheumatology

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis

(2017) Mark C. Genovese et al.   Arthritis & Rheumatology

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

(2016) A Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

(2016) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

(2016) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster

(2016) Kunihiro Yamaoka   DRUG SAFETY

Chemical JAK inhibitors for the treatment of rheumatoid arthritis

(2016) Shingo Nakayamada et al.   EXPERT OPINION ON PHARMACOTHERAPY

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2016) Mark C. Genovese et al.   Arthritis & Rheumatology

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

(2016) Joel M. Kremer et al.   Arthritis & Rheumatology

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

(2015) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

(2015) Roy M. Fleischmann et al.   Arthritis & Rheumatology

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Th17 cytokines and arthritis

(2010) Erik Lubberts   Seminars in Immunopathology

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Intracellular signal pathways: Potential for therapies

(2009) Melissa Mavers et al.   Current Rheumatology Reports

Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)

(2008) Jian-kang Jiang et al.   JOURNAL OF MEDICINAL CHEMISTRY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY